Verrica Pharmaceuticals Inc. (VRCA)
Nasdaq · Healthcare · Biotechnology
$4.31−1.60%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $74.0M
- 52-week range
- $3.28 – $9.82
- 52-week change
- −4.99%
- EPS (trailing)
- −$1.75
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 13, 2026
Fiscal year to Dec 2025
- Revenue
- $35.6M (+370.22%)
- Net income
- −$17.9M
- Operating margin
- −34.2%
- Diluted EPS
- −$1.68
- Free cash flow
- −$17.6M
From the company’s annual report on SEC EDGAR.
About Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Headquarters: West Chester, United States · 76 employees · verrica.com